Loading...
OTCM
FYBGF
Market cap513mUSD
, Last price  
USD
Name

Formycon AG

Chart & Performance

D1W1MN
OTCM:FYBGF chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.83%
Rev. gr., 5y
16.01%
Revenues
70m
-10.32%
20,00049,2520138,430276,17312,585,01716,924,98719,532,99529,003,53642,993,51733,157,17534,226,93936,613,00042,497,00077,696,00069,674,000
Net income
-126m
L
-191,0000-1,290,00000860,326577,518-4,066,129-1,581,3827,098,615-2,293,287-5,925,705-13,290,00035,992,00075,795,000-125,672,000
CFO
-23m
L+135.79%
0038,6002,159,000-16,651,000-32,166517,000-5,038,400-4,171,19813,298,900-1,506,100-5,208,000-13,541,000-18,994,000-9,848,000-23,221,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
URL
https://www.formycon.com/
IPO date
Dec 20, 2010
Employees
224
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT